A first-in-human trial of a divalent small interfering RNA designed to reduce the amount of prion protein (PrP) the brain makes is recruiting people who already have symptoms of prion disease, according to the study's entry on ClinicalTrials.gov (NCT07444580). The trial, called PRiSM and numbered NN112 inside the National Institute of Neurological Disorders and Stroke NeuroNEXT network, is sponsored by the Broad Institute of MIT and Harvard, with Eric Minikel listed as principal investigator and NIH award OT2NS138339 as the funding source. The registration describes an open label, single ascending dose study: screening of up to two weeks, one intrathecal dose of the drug, referred to as PrP-siRNA, then 24 weeks of follow-up, with multiple dose levels tested in sequence and an additional observational arm in which participants receive no investigational drug and are followed for eight weeks. The recorded start date is 15 May 2026 and primary completion is estimated for 14 August 2029. Five United States sites are listed as recruiting: Massachusetts General Hospital, Mayo Clinic in Rochester, Columbia University Medical Center, University Hospitals Cleveland Medical Center and Vanderbilt University Medical Center. The official title names safety, tolerability, pharmacokinetics and pharmacodynamics as the objectives. Survival and cognition are not among them, so the design cannot show whether the drug helps anyone live longer or think more clearly.

The preclinical case for the molecule was published in Nucleic Acids Research on 23 April 2026 by Gentile and colleagues at the Broad Institute and UMass Chan Medical School. All of the efficacy work in that paper was in mice. A mouse targeting version of the drug lowered PrP to 49 percent of normal brain levels in healthy mice; in mice infected with Rocky Mountain Laboratory prions, chronic dosing started before symptoms increased survival time 2.7 fold, while a single dose given after symptom onset increased survival time by 64 percent. The human PRNP targeting candidate was tested in transgenic mice carrying the human gene, where a single 348 microgram dose left 17 percent of human PrP after 30 days and a 52 microgram dose left 49 percent. The authors report that Good Laboratory Practices toxicology studies identified no significant liabilities and that the US Food and Drug Administration cleared an Investigational New Drug application. According to the Broad Institute's announcement of 22 April 2026, the first stage of the trial is to enrol 15 symptomatic patients, each receiving one dose by lumbar puncture, with later participants given larger doses than earlier ones. The investigators' own patient facing notice, posted by Prion Alliance the same day, states plainly that it is not yet known whether PrP-siRNA is safe or effective, and describes eligibility as a physician diagnosis of prion disease supported by a positive RT-QuIC test or a positive genetic test for a PrP mutation, with further criteria assessed at screening.

The trial tests the drug at the stage where PrP lowering has the least animal support. In the same mouse experiments, treatment begun before symptoms bought far more survival time than a single dose after onset, and the researchers have argued from earlier work that lowering PrP by roughly half slows prion disease in mice without preventing onset or halting progression, which is why they sought deeper lowering. Human experience so far is also thin. The only other PrP lowering drug tested in patients, the Ionis antisense oligonucleotide ION717, has been studied in PrProfile (NCT06153966), a first-in-human phase 1/2a trial whose first two dosing regimens are fully enrolled and whose registration now lists recruitment for a third regimen. No results from that trial have been published in a peer reviewed journal, and the investigator blog CureFFI reported in March 2026 that Ionis told the patient community its preliminary data were not sufficient to establish safety, tolerability or efficacy.

For families, the practical content of the registration is narrow and specific: five sites, a single dose, six months of follow-up per participant, and endpoints about tolerability and drug behaviour rather than disease course. Whether a particular person meets the criteria, and whether travel to one of those centres is workable at a given point in the illness, are questions for the treating neurologist and the study team named in the registration.